CinCor Pharma to Participate at Upcoming September Investor Conferences
31 août 2022 08h00 HE
|
CinCor Pharma, Inc.
WALTHAM, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that company management will participate at the following investor conferences: Citi's 17th...
CinCor Pharma Announces Presentation of Phase 1 Clinical Data for Baxdrostat at the Upcoming European Society of Cardiology 2022 Congress
22 août 2022 08h00 HE
|
CinCor Pharma, Inc.
WALTHAM, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that the company will present Phase 1 clinical data on lead candidate baxdrostat as part of a...
CinCor Pharma Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares
15 août 2022 16h17 HE
|
CinCor Pharma, Inc.
WALTHAM, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) (Nasdaq: CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate,...
CinCor Pharma Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
11 août 2022 00h38 HE
|
CinCor Pharma, Inc.
WALTHAM, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) (Nasdaq: CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate,...
CinCor Pharma Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
08 août 2022 17h34 HE
|
CinCor Pharma, Inc.
WALTHAM, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) (Nasdaq: CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate,...
CinCor Reports Second Quarter Financial Results and Provides Corporate Update
08 août 2022 07h15 HE
|
CinCor Pharma, Inc.
Positive topline data in the Phase 2 BrigHtn trial, demonstrating clinically meaningful and statistically significant reduction in blood pressure with baxdrostat in treatment-resistant hypertension ...
CinCor Pharma Announces Positive Topline Data for Phase 2 BrigHtn Trial Evaluating Baxdrostat, its Selective Aldosterone Synthase Inhibitor, in Treatment-Resistant Hypertension
08 août 2022 07h00 HE
|
CinCor Pharma, Inc.
Successfully met the primary endpoint in the BrigHtn trial, delivering a 20.3 mmHg reduction in systolic blood pressure (SBP), or an 11 mmHg (p-value < 0.0001) decline on a placebo-adjusted basis,...
CinCor Pharma Announces Last Patient Randomized in Phase 2 HALO Trial and Initiation of Long-Term Extension Study for Baxdrostat, a Selective Aldosterone Synthase Inhibitor, in Uncontrolled Hypertension
26 juil. 2022 08h00 HE
|
CinCor Pharma, Inc.
Open Label Extension Study Will Evaluate Baxdrostat for Up to 52 Weeks Topline Data for Phase 2 HALO Trial Expected in 2H 2022 Topline Data for Phase 2 BrigHtn Trial Expected in August 2022 ...
CinCor Pharma Doses First Patient in Phase 2 FigHTN-CKD Trial Evaluating the Selective Aldosterone Synthase Inhibitor Baxdrostat (CIN-107) in Patients with Uncontrolled Hypertension and Chronic Kidney Disease
01 juin 2022 08h00 HE
|
CinCor Pharma, Inc.
figHTN-CKD is CinCor’s fourth ongoing Phase 2 clinical trial evaluating baxdrostat (CIN-107) Initial topline data for figHTN-CKD expected in 2H 2023 WALTHAM, Mass., June 01, 2022 (GLOBE NEWSWIRE)...
CinCor Pharma, Inc., Doses First Patient in HALO, a Phase 2 Clinical Trial Evaluating CIN-107, a Selective Aldosterone Synthase Inhibitor, in Patients with Uncontrolled Hypertension and High Plasma Aldosterone
09 déc. 2021 08h00 HE
|
CinCor Pharma, Inc.
CINCINNATI, Dec. 09, 2021 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”), announced today the dosing of the first patient in its Phase 2 clinical trial evaluating CIN-107, a highly selective,...